propallylonal: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 11020 |
| CHEBI ID | 135199 |
| SCHEMBL ID | 713682 |
| MeSH ID | M0136714 |
| Synonym |
|---|
| 4-24-00-01994 (beilstein handbook reference) |
| unii-1er3z9guqh |
| 1er3z9guqh , |
| 545-93-7 |
| AKOS003398682 |
| 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-(2-bromo-2-propenyl)-5-(1-methylethyl)- |
| barbituric acid, 5-(2-bromoallyl)-5-isopropyl- |
| 5-isopropyl-5-bromallylbarbituric acid |
| ibomalum |
| 5-(2-bromoallyl)-5-isopropylbarbituric acid |
| 5-(2'-bromallyl)-5-isopropylbarbituric acid |
| noctal |
| quietal |
| nostral |
| 5-(2-bromo-2-propenyl)-5-(1-methylethyl)-2,4,6(1h,3h,5h)-pyrimidinetrione |
| quietalum |
| 5-isopropyl-5-(2-bromoallyl)barbituate |
| ibomal |
| propaldon |
| einecs 208-896-7 |
| bromoaprobarbital |
| isopropyl-bromallyl-barbitursaeure |
| propallylonal |
| brn 0219943 |
| noctenal |
| kwietal |
| CHEBI:135199 |
| 5-(2-bromoprop-2-enyl)-5-propan-2-yl-1,3-diazinane-2,4,6-trione |
| SCHEMBL713682 |
| 5-(2-bromo-2-propen-1-yl)-5-(1-methylethyl)-2,4,6(1h,3h,5h)-pyrimidinetrione |
| 5-isopropyl-5-(2-bromoallyl)barbiturate |
| 5-isopropyl-5-bromoallylbarbituric acid |
| propallylonal [who-dd] |
| propallylonal [mi] |
| 5-(.beta.-bromoallyl)-5-isopropylbarbituric acid |
| KTGWBBOJAGDSHN-UHFFFAOYSA-N |
| 5-(2-bromo-2-propenyl)-5-isopropyl-2,4,6(1h,3h,5h)-pyrimidinetrione # |
| DTXSID00202906 |
| STL481976 |
| 5-(2-bromoprop-2-en-1-yl)-5-(propan-2-yl)pyrimidine-2,4,6(1h,3h,5h)-trione |
| 5-(2-bromoprop-2-en-1-yl)-5-isopropylpyrimidine-2,4,6(1h,3h,5h)-trione |
| propallylonal, noctal, nostal, quietal, ibomal |
| 5-isopropyl-5-(2-bromoallyl)-barbituric acid |
| Q7250078 |
| Class | Description |
|---|---|
| barbiturates | Members of the class of pyrimidones consisting of pyrimidine-2,4,6(1H,3H,5H)-trione (barbituric acid) and its derivatives. Largest group of the synthetic sedative/hypnotics, sharing a characteristic six-membered ring structure. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 5 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (23.09) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||